Leukemia & Lymphoma Society | Translational Research Program
Event details
| Date | 16.10.2024 |
| Category | Call for proposal |
Aim: LSS funds research on leukemia, lymphoma, myeloma, and all other rare blood cancers. They are dedicated to funding the best science to bring better treatments to patients with every form of blood cancer. The LLS Translational Research Program was created in 1995 with the goal of accelerating clinical applications of laboratory findings relevant to improved diagnosis and management of leukemia, lymphoma, myeloma, and other hematopoietic malignancies
For the 2025 application cycle the foundation will only consider applications that adhere to the following submission guidelines:
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal at https://lls.fluxx.io/. All LOIs should provide brief project information, including a summary of project goals and brief administrative details. Full info here. At the full application stage, an Institutional signature is required; please contact the Research Office for this step.
Deadline:
Letter of Intent – 16 October 2024
Full Application – 21 January 2024
Further information
For the 2025 application cycle the foundation will only consider applications that adhere to the following submission guidelines:
- For small molecule compounds the application must be of in vivo proof of concept (POC) in appropriate mouse models. Alternatively, based on the mechanism of action, an in vitro POC with patient-derived samples may be considered.
- For cellular or immunotherapies, in vivo POC would make for a stronger application. We acknowledge, however, that depending on the type of therapy being developed an in vitro POC may be more appropriate or necessary.
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal at https://lls.fluxx.io/. All LOIs should provide brief project information, including a summary of project goals and brief administrative details. Full info here. At the full application stage, an Institutional signature is required; please contact the Research Office for this step.
Deadline:
Letter of Intent – 16 October 2024
Full Application – 21 January 2024
Further information
- More information about the program, guidelines, and instructions are available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- Informed public
- Free